Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
AD-2022
- Development stage
- Unknown
- Lead developer
- Addpharma
- Modality
- Small Molecules
01
Overview
AD-2022 is a small molecule drug developed by Addpharma for the treatment of cardiovascular and metabolic diseases, specifically targeting essential hypertension and primary hypercholesterolemia. It has been evaluated in clinical trials both as a monotherapy and in combination with another investigational agent, AD-2021. The mechanism of action, specific molecular targets, and detailed pharmacology have not been publicly disclosed. Clinical development has reached Phase 3 for its use in patients with primary hypercholesterolemia and essential hypertension[1][3]. As of May 2025, the global highest R&D status is listed as "Pending," indicating that it has not yet received regulatory approval[1].
Beyond the preview
Go deeper on AD-2022.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on AD-2022.